CN106852144B - 5,6-二氢-4H-苯并[b]噻吩并-[2,3-d]氮杂*衍生物 - Google Patents
5,6-二氢-4H-苯并[b]噻吩并-[2,3-d]氮杂*衍生物 Download PDFInfo
- Publication number
- CN106852144B CN106852144B CN201580054496.3A CN201580054496A CN106852144B CN 106852144 B CN106852144 B CN 106852144B CN 201580054496 A CN201580054496 A CN 201580054496A CN 106852144 B CN106852144 B CN 106852144B
- Authority
- CN
- China
- Prior art keywords
- compound
- rsv
- formula
- salt
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14188494.0 | 2014-10-10 | ||
| EP14188494 | 2014-10-10 | ||
| PCT/GB2015/052944 WO2016055791A1 (en) | 2014-10-10 | 2015-10-08 | Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106852144A CN106852144A (zh) | 2017-06-13 |
| CN106852144B true CN106852144B (zh) | 2019-08-30 |
Family
ID=51842340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580054496.3A Active CN106852144B (zh) | 2014-10-10 | 2015-10-08 | 5,6-二氢-4H-苯并[b]噻吩并-[2,3-d]氮杂*衍生物 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9732098B2 (enExample) |
| EP (2) | EP3204389B1 (enExample) |
| JP (2) | JP2017531039A (enExample) |
| KR (1) | KR20170058921A (enExample) |
| CN (1) | CN106852144B (enExample) |
| AU (1) | AU2015329789B2 (enExample) |
| BR (1) | BR112017005104B1 (enExample) |
| CA (1) | CA2957868C (enExample) |
| EA (1) | EA201790796A8 (enExample) |
| IL (1) | IL250823A0 (enExample) |
| MX (1) | MX2017004652A (enExample) |
| SG (1) | SG11201701184WA (enExample) |
| WO (2) | WO2016055792A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201701184WA (en) * | 2014-10-10 | 2017-03-30 | Pulmocide Ltd | Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative |
| JP6694886B2 (ja) | 2014-12-18 | 2020-05-20 | プルモシデ リミテド | ４，５−ジヒドロ−６Ｈ−チエノ［３，２−ｄ］ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス（ＲＳＶ）感染を治療するためのその使用 |
| NZ739226A (en) | 2015-07-22 | 2022-11-25 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| EP3402799B1 (en) | 2016-01-15 | 2022-05-04 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| KR20180108598A (ko) * | 2016-02-03 | 2018-10-04 | 얀센 사이언시즈 아일랜드 유씨 | Rsv의 치료를 위한 조합 생성물 |
| WO2017175000A1 (en) * | 2016-04-08 | 2017-10-12 | Pulmocide Limited | Compounds |
| WO2018129287A1 (en) | 2017-01-06 | 2018-07-12 | Enanta Pharmaceuticals, Inc. | Heteroaryldiazepine derivatives as rsv inhibitors |
| AU2018221820B2 (en) | 2017-02-16 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
| US10752598B2 (en) | 2017-06-07 | 2020-08-25 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as RSV inhibitors |
| WO2019006295A1 (en) * | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| US10851115B2 (en) | 2017-06-30 | 2020-12-01 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| BR112020006334A2 (pt) | 2017-09-29 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | combinação de agentes farmacêuticos como inibidores de rsv |
| JP7228588B2 (ja) | 2017-11-13 | 2023-02-24 | エナンタ ファーマシューティカルズ インコーポレイテッド | ベンゾジアゼピン－２－オンおよびベンゾアゼピン－２－オン誘導体の分割方法 |
| US10647711B2 (en) | 2017-11-13 | 2020-05-12 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as RSV inhibitors |
| US10975094B2 (en) | 2018-04-11 | 2021-04-13 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| US11254664B2 (en) | 2019-03-18 | 2022-02-22 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as RSV inhibitors |
| WO2020210246A1 (en) * | 2019-04-09 | 2020-10-15 | Enanta Pharmaceuticals, Inc, | Heterocyclic compounds as rsv inhibitors |
| KR20220101083A (ko) | 2019-10-04 | 2022-07-19 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스 헤테로사이클릭 화합물 |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
| US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| JP2024507561A (ja) | 2021-02-26 | 2024-02-20 | エナンタ ファーマシューティカルズ インコーポレイテッド | 抗ウイルス複素環式化合物 |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| WO2023211997A1 (en) | 2022-04-27 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011005842A1 (en) * | 2009-07-09 | 2011-01-13 | Gilead Sciences, Inc. | Anti-rsv compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5693635A (en) | 1993-07-29 | 1997-12-02 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| CA2371308A1 (en) | 1999-04-28 | 2000-11-02 | Aventis Pharma Deutschland Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
| JP2011509261A (ja) * | 2008-01-07 | 2011-03-24 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途向けの化合物 |
| PT2488486T (pt) | 2009-10-13 | 2019-11-05 | Ligand Pharm Inc | Compostos de moléculas pequenas de mimética de fator de crescimento hematopoiético e utilizações dos mesmos |
| AU2011283684B2 (en) | 2010-07-29 | 2015-08-27 | Rigel Pharmaceuticals, Inc. | AMPK-activating heterocyclic compounds and methods for using the same |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| EP3177299A4 (en) | 2014-08-05 | 2018-04-04 | Alios Biopharma, Inc. | Combination therapy for treating a paramyxovirus |
| SG11201701184WA (en) | 2014-10-10 | 2017-03-30 | Pulmocide Ltd | Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative |
| EP3402799B1 (en) | 2016-01-15 | 2022-05-04 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| KR20180108598A (ko) | 2016-02-03 | 2018-10-04 | 얀센 사이언시즈 아일랜드 유씨 | Rsv의 치료를 위한 조합 생성물 |
| US10851115B2 (en) | 2017-06-30 | 2020-12-01 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
-
2015
- 2015-10-08 SG SG11201701184WA patent/SG11201701184WA/en unknown
- 2015-10-08 MX MX2017004652A patent/MX2017004652A/es unknown
- 2015-10-08 WO PCT/GB2015/052945 patent/WO2016055792A1/en not_active Ceased
- 2015-10-08 JP JP2017538467A patent/JP2017531039A/ja not_active Withdrawn
- 2015-10-08 KR KR1020177006394A patent/KR20170058921A/ko not_active Withdrawn
- 2015-10-08 AU AU2015329789A patent/AU2015329789B2/en active Active
- 2015-10-08 WO PCT/GB2015/052944 patent/WO2016055791A1/en not_active Ceased
- 2015-10-08 BR BR112017005104-4A patent/BR112017005104B1/pt active IP Right Grant
- 2015-10-08 EA EA201790796A patent/EA201790796A8/ru unknown
- 2015-10-08 CN CN201580054496.3A patent/CN106852144B/zh active Active
- 2015-10-08 JP JP2017538466A patent/JP6675407B2/ja active Active
- 2015-10-08 US US15/305,003 patent/US9732098B2/en active Active
- 2015-10-08 US US15/516,809 patent/US10189863B2/en active Active
- 2015-10-08 CA CA2957868A patent/CA2957868C/en active Active
- 2015-10-08 EP EP15784440.8A patent/EP3204389B1/en active Active
- 2015-10-08 EP EP15782045.7A patent/EP3204388B1/en active Active
-
2017
- 2017-02-27 IL IL250823A patent/IL250823A0/en active IP Right Grant
- 2017-07-06 US US15/642,637 patent/US9926335B2/en active Active
-
2018
- 2018-02-22 US US15/902,077 patent/US10035810B2/en active Active
- 2018-07-12 US US16/033,464 patent/US10273249B2/en active Active
-
2019
- 2019-03-11 US US16/298,460 patent/US10472375B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011005842A1 (en) * | 2009-07-09 | 2011-01-13 | Gilead Sciences, Inc. | Anti-rsv compounds |
Non-Patent Citations (1)
| Title |
|---|
| Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor;Hui Xiong，等;《Bioorganic & Medicinal Chemistry Letters》;20131016;第23卷(第24期);第6789-6793页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106852144B (zh) | 5,6-二氢-4H-苯并[b]噻吩并-[2,3-d]氮杂*衍生物 | |
| US10626126B2 (en) | Compounds | |
| EP3233867B1 (en) | 4,5-dihydro-6h-thieno[3,2-d]benzazepine derivatives and their use to treat respiratory syncytial virus (rsv) infections | |
| EP2776416B1 (en) | Pharmaceutical compounds | |
| TWI515193B (zh) | 用於治療呼吸道融合病毒感染之化合物 | |
| JP2022507118A (ja) | 呼吸器疾患の処置のための化合物及び組成物 | |
| AU2022353486A1 (en) | Pharmaceutical composition containing triazine derivative | |
| CN101583614B (zh) | 用于治疗呼吸道合胞体病毒感染的多环试剂 | |
| HK1242318A1 (en) | Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative | |
| HK1242318B (en) | Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: S*F*Hunt Inventor after: S*T*O'Neills Inventor after: V.Sheberkin Inventor after: E*A*F*Fudes Inventor after: P.J.Murray Inventor after: D.W Brooks Inventor after: Itoh Kazuhiro Inventor after: P.Strong Inventor after: M*S*Coates Inventor before: S*F*Hunt Inventor before: S*T*O'Neills Inventor before: V.Sheberkin Inventor before: E*A*F*Fudes Inventor before: P.J.Murray Inventor before: D.W Brooks Inventor before: Itoh Kazuhiro Inventor before: P.Strong |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |